Strategic partnerships Multiply Labs has active collaborations with Thermo Fisher Scientific, Legend Biotech, Retro Biosciences, and Wilson Wolf, plus a recent CPC Biotech partnership. These alliances indicate strong cross‑sell and co‑development opportunities to expand automated manufacturing capabilities for cell therapies and bioprocess automation.

Scaleable demand With revenue in the high tens of millions and a financing round totaling over 41 million, Multiply Labs demonstrates capital availability and customer demand for scalable robotic systems in cell therapy manufacturing, signaling a receptive market for expanded automation deployments.

Expanded use cases Recent integrations and collaborations with Portal Biotechnologies and G‑Rex bioreactors via Wilson Wolf show diversification in automation applications, creating upsell potential for broader robotic automation solutions across cells, inputs, and bioreactor workflows.

Global market fit Partnering with industry leaders across biopharma and cell therapy space, including Thermo Fisher Scientific and Legend Biotech, indicates a validated value proposition for large‑scale manufacturing automation that can be leveraged to win additional enterprise accounts.

Technology readiness Utilizing a tech stack centered on AWS, Docker, SOLIDWORKS, and data analytics tools (Tableau, Piwik PRO) alongside scalable cloud and design capabilities suggests readiness to integrate with customers’ digital manufacturing ecosystems, enabling easier procurement and deployment.